

EndoDiagnosis, Inc Exhibits TIER-1 ENDOSURE Diagnostic Test for Endometriosis at AAGL 2025 in Vancouver, BC, Canada

November 04, 2025

Edmonton, AB - November 04, 2025 - PRESSADVANTAGE -

Vancouver, BC?EndoDiagnosis, Inc., is exhibiting at the American Association of Gynecologic Laparoscopists (AAGL) Global Congress taking place November 9-11, 2025, in Vancouver, British Columbia. Healthcare professionals, researchers, and industry leaders are invited to Booth #540 where senior management of EndoDiagnosis Inc and ENDOSURE, INC provide comprehensive information about the Non-Invasive, 30-Minute, Highly Accurate, TIER-1 ENDOSURE TEST for endometriosis.

Endometriosis affects 1 in 10 women worldwide, yet accurate and rapid non-invasive diagnosis has remained elusive. The absence of a Tier-1 test has led to an average diagnostic, time delay from first symptom onset to diagnosis, of 8.6 years globally. Tier-1 ENDOSURE TEST drops this diagnostic gap to 30-minutes.¹

"I've witnessed firsthand the frustration and desperation that close to 200 million women worldwide experience," shares Maria Porcellato, CEO of the EndoDiagnosis team. "They want to know why they have to struggle with painful symptoms or infertility for years. Our mission is to help provide clarity in 30-minutes with the Tier-1 ENDOSURE TEST, empowering clinicians, and the women they serve, with a means for a rapid, accurate diagnosis."

For clinicians, the current diagnostic limitations mean spending valuable time and healthcare resources on lengthy diagnostic processes rather than focusing on patient care and personalized symptom management.

At the heart of EndoDiagnosis, Inc.'s mission lies the ENDOSURE TEST?the world's only TIER-1, rapid diagnostic test for endometriosis, authorized for sale by Health Canada. Endometriosis is a challenging and complex disease that along with being present in the pelvic cavity, can also be found in other areas such as the thoracic cavity, spine, brain? essentially anywhere in the body. The ENDOSURE TEST can detect

endometriosis in any anatomic location, in any patient age and in any stage of disease progression, making it a valuable tool for early intervention and comprehensive care.¹

At the AAGL 2025 conference, abstracts from two validating research studies focused on clinical utility of GIMA biomarkers in endometriosis diagnosis will be presented in oral sessions on November 10, 2025.

Dr. Marina Andres will present Abstract #14863, titled "Non-Invasive Electroviscerography for the Diagnosis of Endometriosis: A Prospective Pilot Study." This groundbreaking research, conducted at two tertiary hospitals in São Paulo, Brazil, demonstrates the real-world application and effectiveness of ENDOSURE technology in a clinical setting.

Dr. Mark Noar, speaking on behalf of Dr. Panayiotis Tanos, will present Abstract #14608: "Defining the Role of the Gastrointestinal Myoelectrical Activity (GIMA) Biomarker in the Diagnosis of Endometriosis." This research from CHU Brugmann in Brussels demonstrates GIMA biomarkers' ability to identify cases of superficial endometriosis that conventional imaging methods missed entirely. This capability addresses a critical gap in current diagnostic approaches, where superficial endometriosis often goes undetected despite causing significant patient symptoms.

The positive impact of rapid, accurate endometriosis diagnosis extends far beyond individual patient experiences, creating a ripple effect of benefits throughout the healthcare system.

For patients, Tier-1 diagnosis with ENDOSURE means identifying the root causes of pain and possible cause for infertility years sooner. This early identification enables prompt symptom management, minimizes disease progression, and enhances future fertility options. Receiving timely answers brings immense psychological relief, enabling patients to shift from confusion and disappointment toward making knowledgeable choices and pursuing treatments from their doctor tailored specifically to their needs.

For clinicians, rapid diagnosis transforms the patient-provider relationship. Instead of spending years navigating diagnostic uncertainty, healthcare teams can focus their expertise on patient care rather than diagnosis. This shift allows for earlier intervention in managing often painful symptoms and implementing strategies to limit disease progression before it significantly impacts quality of life and fertility.

For healthcare systems, insurance companies, and employers, the economic implications are substantial. Studies demonstrate that rapid diagnosis versus the current more than 5-year average delay in Canada reduces overall healthcare costs by 37% and endometriosis-specific costs by 56%.² These savings result from decreased diagnostic procedures, reduced emergency department visits, fewer specialist referrals, and more targeted treatment approaches.

Citations:

Noar, M.; Mathias, J.; Kolatkar, A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. *J. Clin. Med.* 2024, 13, 2866. <https://doi.org/10.3390/jcm13102866>

Surrey E, Soliman AM, Trenz H, Blauer-Peterson C, Sluis A., " Impact of Endometriosis Diagnostic Delays on Healthcare Resource Utilization and Costs.", *Adv Ther.* 2020;37(3):1087-1099. doi:10.1007/s12325-019-01215-xHealth Canada. Medical Devices Active Licence Listing [Internet]. Ottawa (ON): Government of Canada; [cited 2025 Oct 27].

###

For more information about EndoDiagnosis Inc., contact the company here: EndoDiagnosis Inc. Carolyn Plican 1-833-439-3636 info@endodiagnosis.com 6903 142 Ave NW, Edmonton, AB T5C 2P1

EndoDiagnosis Inc.

EndoDiagnosis addresses the need for faster, more accurate endometriosis diagnosis in Canada. Led by Maria Porcellato, Carolyn Plican, and Dr. Mary Ellen Haggerty, it exclusively distributes ENDOSURE a Health Canada authorized test with 1 hour results.

Website: <https://endodiagnosis.com/>

Email: info@endodiagnosis.com

Phone: 1-833-439-3636



